共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis显示文摘AIM: To investigate the prognostic significance of insulin-like growth factor-binding protein 3(IGFBP-3) in patients with cirrhosis.METHODS: Prospective study that included two cohorts: outpatients with stable cirrhosis(n = 138) and patients hospitalized for acute decompensation(n = 189). Development of complications, mortality or liver transplantation was assessed by periodical phone calls and during outpatient visits. The cohort of stable cirrhosis also underwent clinical and laboratory evaluation yearly(2013 and 2014) in predefined study visits. In patients with stable cirrhosis, IGFBP-3 levels were measured at baseline(2012) and at second re-evaluation(2014). In hospitalized subjects, IGFBP-3 levels were measured in serum samples collected in the first and in the third day after admission and stored at-80 ℃. IGFBP-3 levels were measured by immunochemiluminescence.RESULTS: IGFBP-3 levels were lower in hospitalized patients as compared to outpatients(0.94 mcg/mL vs 1.69 mcg/m L, P < 0.001) and increased after liver transplantation(3.81 mcg/m L vs 1.33 mcg/mL, P = 0.008). During the follow-up of the stable cohort, 17 patients died and 11 received liver transplantation. Bivariate analysis showed that death or transplant was associated with lower IGFBP-3 levels(1.44 mcg/mL vs 1.74 mcg/m L, P = 0.027). The Kaplan-Meier transplant-free survival probability was 88.6% in patients with IGFBP-3 ≥ 1.67 mcg/mL and 72.1% for those with IGFBP3 < 1.67 mcg/mL(P = 0.015). In the hospitalized cohort, 30-d mortality was 24.3% and was independently associated with creatinine, INR, SpO_2/FiO_2 ratio and IGFBP-3 levels in the logistic regression. The 90-d transplant-free survival probability was 80.4% in patients with IGFBP-3 ≥ 0.86 mcg/mL and 56.1% for those with IGFBP3 < 0.86 mcg/mL(P < 0.001). CONCLUSION: Lower IGFBP-3 levels were associated with worse outcomes in patients with cirrhosis, and might represent a promising prognostic tool that can be incorporated in clinical practice. | Carina Gabriela Correa Bruno da Silveira Colombo Marcelo Fernando Ronsoni Pedro Eduardo Soares e Silva Leonardo Fayad Telma Erotides Silva Letícia Muraro Wildner Maria Luiza Bazzo Esther Buzaglo Dantas-Correa Janaína Luz Narciso-Schiavon Leonardo de Lucca Schiavon | 2016 | World Journal of Hepatology2016，8，17： | 1 |
| 2 | 腹腔镜联合多肽类激素类药物治疗子宫内膜异位症疗效分析显示文摘目的:探讨腹腔镜联合多肽类激素类药物治疗子宫内膜异位症的疗效。方法:选择我院2013年3月-2014年3月收治的124例子宫内膜异位症患者,分为ABC三组,A组术后不用任何药物进行巩固治疗,B组术后使用米非司酮治疗,C组术后使用孕三烯酮治疗。观察三组患者术后复发率、妊娠结局及药物副作用。结果:B、C两组患者症状明显缓解,较A组显著较高;术后回访一年,B、C两组的复发率及术后妊娠率无显著差异,但都优于A组患者,差异有统计学意义(p<0.05)。结论:针对子宫内膜异位症患者实施腹腔镜联合多肽类激素类药物治疗,有助于提高患者妊娠率、降低复发率并改善患者卵巢功能,值得临床推广。 | 王丹 | 2015 | 世界最新医学信息文摘2015，0，57： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员